Dr. Muthupandian Saravanan is currently a Professor in the Department of Pharmacology at Saveetha University, SIMATS, Chennai, India. He has a degree in Microbiology from Madurai Kamaraj University and a Doctorate with Specialization in Medical Microbiology and Nanomedicine from Sathyabama University, India. As a Post-Doctoral Researcher at the Hebrew University of Jerusalem, he studied nano-biomaterials and their biomedical applications. He later worked as Associate Professor, under the United Nation Development Program in Department of Medical Microbiology and Immunology at Mekelle University in Ethiopia. He has published papers in high impact journals such as the Lancet and Nature. He has participated in more than 75 national and international conferences and reviewed of more than 100 international peer-reviewed journals. He has served as guest editor/ co-editor for reputed PubMed and Scopus indexed journals. He has received many fellowships and awards, notably the IET- Nanobiotechnology premium Awards in 2019 and 2020. Hamed Barabadi (PharmD, PhD) is an assistant professor at the Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. He received a PhD degree from Shahid Beheshti University of Medical Sci-ences, Tehran, Iran, in 2019. He graduated as a Doctor of Pharmacy (PharmD) from Mazandaran University of Medical Sciences, Sari, Iran, in 2014. He owns to his credit a number of research papers, book chapters, and edited books with more than 6000 citations and h-index of 52. He has received many awards such as IET—Nanobiotechnology Premium Awards in 2019 and 2020. Dr. Barabadi has been featured among the World’s Top 2% scientists list, according to a Stanford University study 2020 and 2022. He is the guest editor/editor for various reputed indexed journals such as Current Nanomedicine, Nanoscience and Nanotechnology-Asia, Frontiers in Pharmacology, MDPI International Journal of Molecular Sciences, MDPI Molecules, and others. His research interests lie in the area of pharmaceutical nanobiotechnology, ranging from green synthesis, characterization, and optimization of nanobiomaterials to their pharmaceutical potential evaluations, such as anticancer, antimicrobial, antioxidant, etc. Moreover, he has collaborated actively with researchers in several other disciplines of pharmaceutical sciences, particularly the nanoformulation of drugs for drug delivery systems and nanomedicine. Dr. Ebrahim Mostafavi has so far received training at Stanford University School of Medicine (PostDoc), Northeastern University (PhD), Harvard Medical School (Researcher), and University of Tehran (MSc and BSc). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as cancer diagnostics and therapeutics, tissue engineering and regenerative medicine, biosensing, and infectious diseases. Dr. Mostafavi serves as an associate editor-in-chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, and so on He is also an editorial board member of more than 30 impactful and prestigious biomedical and materials science journals. His scholarly work comprises more than 200 publications with an H-index of 36 (i10-index of 105), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, and Global Health) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/ translational medicine. Dr. Thomas J. Webster is a pioneering professor in biomedical engineering, recognized for his leadership in academia and industry. His research focuses on applying nanotechnology to develop advanced materials for medical use, significantly improving healthcare outcomes. Dr. Webster has held prominent faculty positions in top U.S. and international universities, chaired departments, and directed international centers in biomaterials. He has also founded numerous companies translating his research into FDA-approved medical products. Widely published and a sought-after speaker, his work has been featured in major media outlets and science museums. Dr. Webster is renowned for organizing global conferences and symposia on nanomedicine and biomaterials, fostering interdisciplinary collaboration. He is the recipient of numerous prestigious awards and fellowships from leading scientific and medical organizations, demonstrating his impact and innovation in biomaterials, nanomedicine, and biomedical engineering.

• 1. Novel medicinal and synthetic chemistry strategies against antimicrobial resistance 2. Strategies of surface engineering/modifications for reversing antibiotic resistance 3. Overcoming antimicrobial resistance by nanoparticles4. Nano-targeted drug delivery approaches for biofilm-associated infections 5. Nano-targeted drug delivery approaches for bacterial infections 6. Nano-structured drug delivery approaches for fungal infections 7. Nano-targeted drug delivery approaches for viral infections 8. Biogenic metal nanomaterials to combat antimicrobial resistance 9. Nanotechnology-based approaches against COVID-19 10. Nanotechnology-based approaches for antitubercular drug delivery 11. Nano-targeted drug delivery for parasitic infections 12. Nanovaccines delivery approaches against infectious diseases 13. Nanotechnology-based therapies for skin wound regeneration 14. Photodynamic therapy with nanomaterials to combat microbial infections 15. Application of extracellular vesicles in the diagnosis and treatment of infection and bacterial resistance 16. Aptamer-based nanomaterials for drug/gene delivery systems and diagnostics to combat microbial infections 17. Monoclonal antibodies for diagnostic and therapeutic systems to combat microbial infections 18. Nanoparticle-based antimicrobial for dental restorative materials 19. Toxicity and biocompatibility of nanomaterials: In vivo studies 20. Oligonucleotides: A therapeutic approach for tackling antimicrobial resistance

Dr. Muthupandian Saravanan is currently a Professor in the Department of Pharmacology at Saveetha University, SIMATS, Chennai, India. He has a degree in Microbiology from Madurai Kamaraj University and a Doctorate with Specialization in Medical Microbiology and Nanomedicine from Sathyabama University, India. As a Post-Doctoral Researcher at the Hebrew University of Jerusalem, he studied nano-biomaterials and their biomedical applications. He later worked as Associate Professor, under the United Nation Development Program in Department of Medical Microbiology and Immunology at Mekelle University in Ethiopia. He has published papers in high impact journals such as the Lancet and Nature. He has participated in more than 75 national and international conferences and reviewed of more than 100 international peer-reviewed journals. He has served as guest editor/ co-editor for reputed PubMed and Scopus indexed journals. He has received many fellowships and awards, notably the IET- Nanobiotechnology premium Awards in 2019 and 2020. Hamed Barabadi (PharmD, PhD) is an assistant professor at the Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. He received a PhD degree from Shahid Beheshti University of Medical Sci-ences, Tehran, Iran, in 2019. He graduated as a Doctor of Pharmacy (PharmD) from Mazandaran University of Medical Sciences, Sari, Iran, in 2014. He owns to his credit a number of research papers, book chapters, and edited books with more than 6000 citations and h-index of 52. He has received many awards such as IET—Nanobiotechnology Premium Awards in 2019 and 2020. Dr. Barabadi has been featured among the World’s Top 2% scientists list, according to a Stanford University study 2020 and 2022. He is the guest editor/editor for various reputed indexed journals such as Current Nanomedicine, Nanoscience and Nanotechnology-Asia, Frontiers in Pharmacology, MDPI International Journal of Molecular Sciences, MDPI Molecules, and others. His research interests lie in the area of pharmaceutical nanobiotechnology, ranging from green synthesis, characterization, and optimization of nanobiomaterials to their pharmaceutical potential evaluations, such as anticancer, antimicrobial, antioxidant, etc. Moreover, he has collaborated actively with researchers in several other disciplines of pharmaceutical sciences, particularly the nanoformulation of drugs for drug delivery systems and nanomedicine. Dr. Ebrahim Mostafavi has so far received training at Stanford University School of Medicine (PostDoc), Northeastern University (PhD), Harvard Medical School (Researcher), and University of Tehran (MSc and BSc). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as cancer diagnostics and therapeutics, tissue engineering and regenerative medicine, biosensing, and infectious diseases. Dr. Mostafavi serves as an associate editor-in-chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, and so on He is also an editorial board member of more than 30 impactful and prestigious biomedical and materials science journals. His scholarly work comprises more than 200 publications with an H-index of 36 (i10-index of 105), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, and Global Health) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/ translational medicine. Dr. Thomas J. Webster is a pioneering professor in biomedical engineering, recognized for his leadership in academia and industry. His research focuses on applying nanotechnology to develop advanced materials for medical use, significantly improving healthcare outcomes. Dr. Webster has held prominent faculty positions in top U.S. and international universities, chaired departments, and directed international centers in biomaterials. He has also founded numerous companies translating his research into FDA-approved medical products. Widely published and a sought-after speaker, his work has been featured in major media outlets and science museums. Dr. Webster is renowned for organizing global conferences and symposia on nanomedicine and biomaterials, fostering interdisciplinary collaboration. He is the recipient of numerous prestigious awards and fellowships from leading scientific and medical organizations, demonstrating his impact and innovation in biomaterials, nanomedicine, and biomedical engineering.

• 1. Novel medicinal and synthetic chemistry strategies against antimicrobial resistance 2. Strategies of surface engineering/modifications for reversing antibiotic resistance 3. Overcoming antimicrobial resistance by nanoparticles4. Nano-targeted drug delivery approaches for biofilm-associated infections 5. Nano-targeted drug delivery approaches for bacterial infections 6. Nano-structured drug delivery approaches for fungal infections 7. Nano-targeted drug delivery approaches for viral infections 8. Biogenic metal nanomaterials to combat antimicrobial resistance 9. Nanotechnology-based approaches against COVID-19 10. Nanotechnology-based approaches for antitubercular drug delivery 11. Nano-targeted drug delivery for parasitic infections 12. Nanovaccines delivery approaches against infectious diseases 13. Nanotechnology-based therapies for skin wound regeneration 14. Photodynamic therapy with nanomaterials to combat microbial infections 15. Application of extracellular vesicles in the diagnosis and treatment of infection and bacterial resistance 16. Aptamer-based nanomaterials for drug/gene delivery systems and diagnostics to combat microbial infections 17. Monoclonal antibodies for diagnostic and therapeutic systems to combat microbial infections 18. Nanoparticle-based antimicrobial for dental restorative materials 19. Toxicity and biocompatibility of nanomaterials: In vivo studies 20. Oligonucleotides: A therapeutic approach for tackling antimicrobial resistance

Dr. Muthupandian Saravanan is currently a Professor in the Department of Pharmacology at Saveetha University, SIMATS, Chennai, India. He has a degree in Microbiology from Madurai Kamaraj University and a Doctorate with Specialization in Medical Microbiology and Nanomedicine from Sathyabama University, India. As a Post-Doctoral Researcher at the Hebrew University of Jerusalem, he studied nano-biomaterials and their biomedical applications. He later worked as Associate Professor, under the United Nation Development Program in Department of Medical Microbiology and Immunology at Mekelle University in Ethiopia. He has published papers in high impact journals such as the Lancet and Nature. He has participated in more than 75 national and international conferences and reviewed of more than 100 international peer-reviewed journals. He has served as guest editor/ co-editor for reputed PubMed and Scopus indexed journals. He has received many fellowships and awards, notably the IET- Nanobiotechnology premium Awards in 2019 and 2020. Hamed Barabadi (PharmD, PhD) is an assistant professor at the Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. He received a PhD degree from Shahid Beheshti University of Medical Sci-ences, Tehran, Iran, in 2019. He graduated as a Doctor of Pharmacy (PharmD) from Mazandaran University of Medical Sciences, Sari, Iran, in 2014. He owns to his credit a number of research papers, book chapters, and edited books with more than 6000 citations and h-index of 52. He has received many awards such as IET—Nanobiotechnology Premium Awards in 2019 and 2020. Dr. Barabadi has been featured among the World’s Top 2% scientists list, according to a Stanford University study 2020 and 2022. He is the guest editor/editor for various reputed indexed journals such as Current Nanomedicine, Nanoscience and Nanotechnology-Asia, Frontiers in Pharmacology, MDPI International Journal of Molecular Sciences, MDPI Molecules, and others. His research interests lie in the area of pharmaceutical nanobiotechnology, ranging from green synthesis, characterization, and optimization of nanobiomaterials to their pharmaceutical potential evaluations, such as anticancer, antimicrobial, antioxidant, etc. Moreover, he has collaborated actively with researchers in several other disciplines of pharmaceutical sciences, particularly the nanoformulation of drugs for drug delivery systems and nanomedicine. Dr. Ebrahim Mostafavi has so far received training at Stanford University School of Medicine (PostDoc), Northeastern University (PhD), Harvard Medical School (Researcher), and University of Tehran (MSc and BSc). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as cancer diagnostics and therapeutics, tissue engineering and regenerative medicine, biosensing, and infectious diseases. Dr. Mostafavi serves as an associate editor-in-chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, and so on He is also an editorial board member of more than 30 impactful and prestigious biomedical and materials science journals. His scholarly work comprises more than 200 publications with an H-index of 36 (i10-index of 105), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, and Global Health) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/ translational medicine. Dr. Thomas J. Webster is a pioneering professor in biomedical engineering, recognized for his leadership in academia and industry. His research focuses on applying nanotechnology to develop advanced materials for medical use, significantly improving healthcare outcomes. Dr. Webster has held prominent faculty positions in top U.S. and international universities, chaired departments, and directed international centers in biomaterials. He has also founded numerous companies translating his research into FDA-approved medical products. Widely published and a sought-after speaker, his work has been featured in major media outlets and science museums. Dr. Webster is renowned for organizing global conferences and symposia on nanomedicine and biomaterials, fostering interdisciplinary collaboration. He is the recipient of numerous prestigious awards and fellowships from leading scientific and medical organizations, demonstrating his impact and innovation in biomaterials, nanomedicine, and biomedical engineering.

• 1. Novel medicinal and synthetic chemistry strategies against antimicrobial resistance 2. Strategies of surface engineering/modifications for reversing antibiotic resistance 3. Overcoming antimicrobial resistance by nanoparticles4. Nano-targeted drug delivery approaches for biofilm-associated infections 5. Nano-targeted drug delivery approaches for bacterial infections 6. Nano-structured drug delivery approaches for fungal infections 7. Nano-targeted drug delivery approaches for viral infections 8. Biogenic metal nanomaterials to combat antimicrobial resistance 9. Nanotechnology-based approaches against COVID-19 10. Nanotechnology-based approaches for antitubercular drug delivery 11. Nano-targeted drug delivery for parasitic infections 12. Nanovaccines delivery approaches against infectious diseases 13. Nanotechnology-based therapies for skin wound regeneration 14. Photodynamic therapy with nanomaterials to combat microbial infections 15. Application of extracellular vesicles in the diagnosis and treatment of infection and bacterial resistance 16. Aptamer-based nanomaterials for drug/gene delivery systems and diagnostics to combat microbial infections 17. Monoclonal antibodies for diagnostic and therapeutic systems to combat microbial infections 18. Nanoparticle-based antimicrobial for dental restorative materials 19. Toxicity and biocompatibility of nanomaterials: In vivo studies 20. Oligonucleotides: A therapeutic approach for tackling antimicrobial resistance